Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.